Skip to content
DraconiticResearch
Search Sources API
184,937 studies31 sourcesUpdated 28 min ago
Peer-reviewedCC BY-NC-ND 4.0In Vivo

Prognostic Significance of the ESTRO/EORTC Classification of Oligometastatic Disease for Colorectal Cancer Patients With Uncommon Metastases Treated With Definitive Radiotherapy

  • TAO-WEI KE1,2
  • WILLIAM TZU-LIANG CHEN1,3,4
  • SHENG-CHI CHANG1,4,5
  • CHE-HUNG LIN6
  • YU-MIN LIAO6
  • YUAN-YAO TSAI1
  • SU-PENG YEH4,6
  • HUA-CHE CHIANG7
  • HWEI-MING WANG1
  • JI-AN LIANG4,8
  • CHIA-CHIN LI8
  • CHUN-RU CHIEN4,8
8 affiliations
  1. 1Department of Colorectal Surgery, China Medical University Hospital, Taichung, Taiwan, R.O.C.
  2. 2School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan, R.O.C.
  3. 3Department of Colorectal Surgery, China Medical University Hsinchu Hospital, Hsinchu, Taiwan, R.O.C.
  4. 4School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan, R.O.C.
  5. 5Department of Colorectal Surgery, Taichung Municipal Geriatric Rehabilitation General Hospital Managed by China Medical University, China Medical University, Taichung, Taiwan, R.O.C.
  6. 6Division of Hematology and Oncology, China Medical University Hospital, Taichung, Taiwan, R.O.C.
  7. 7Department of Colorectal Surgery, Asia University Hospital, Taichung, Taiwan, R.O.C.
  8. 8Department of Radiation Oncology, China Medical University Hospital, Taichung, Taiwan, R.O.C.
Read full textPDFDOICite

Abstract

Background/Aim: Prognostic significance of ESTRO/EORTC classification (Lancet Oncol. 21:e18-e28) for colorectal cancer patients with oligometastatic disease at uncommon sites unfit for surgery is unclear.

Patients and Methods: We conducted a retrospective study of colorectal cancer patients with post-surgical oligometastatic disease at uncommon sites treated with definitive radiotherapy. We identified eligible patients via in-house databases. Clinical, disease, treatment, and outcome data were obtained through medical-record review, with classifications determined by consensus among the attending physicians. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method. Cox regression models were used to investigate the potential prognostic factors including the ESTRO/EORTC classification. We also estimated the incidence of local progression.

Results: We identified 59 eligible patients treated from Dec 2012 to Sep 2025. After a median follow-up of 28 months (range=3-145 months), the 5-year OS, PFS, and incidence of local progression were 24%, 10%, 66% respectively. Induced oligoprogression was associated with inferior PFS (adjusted hazard ratio 3.82, p=0.004) but not OS.

Conclusion: ESTRO/EORTC classification was associated with outcomes for colorectal cancer patients with oligometastatic disease at uncommon sites treated with definitive radiotherapy. Future studies are needed to validate our findings.

Related

  1. Prognostic stratification by the ESTRO/EORTC oligometastatic classification and simplified binary approaches in lung cancer patients treated with stereotactic ablative radiotherapy.
    Dan Yao, Xue-Ru Zhu, Jin-Dong Guo +8
    BMC cancerPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  2. Prognostic Significance of Cellular Cannibalism in Colorectal Tumors
    Sumru Cagaptay, Anil Aysal Agalar, Ozgul Sagol +6
    International Journal of Surgical PathologyPeer-reviewedCC BY-NC 4.0Full textOncologyPMC
  3. Prognostic significance of tumor budding and poorly differentiated clusters in colorectal cancer : A retrospective study
    Mehmet Doğan, Ayça Dilşad Çağlayan, Adem Çağlayan +2
    MedicinePeer-reviewedCC BY-NCFull textGeneral medicineEurope PMCPMC
  4. Immunohistochemical Classification and Prognostic Significance of Germinal Center-like and Memory Cell-like Subtypes of Follicular Lymphoma Using FOXP1, LMO2, CD22, and MUM1.
    Tülay Koç, Sedanur Aydın, Zeynep Öztürk +1
    International journal of molecular sciencesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Intramedullary Spinal Cord Metastasis From Oligometastatic Melanoma of Unknown Primary Treated With Stereotactic Body Radiotherapy.
    Karen Anne Aguirre-Meneses, Justin Owen, Benjamin Mou
    CureusPeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMC

Cite

BibTeXRIS
BibTeX
@article{taowei2026prognostic,
  title = {{Prognostic Significance of the ESTRO/EORTC Classification of Oligometastatic Disease for Colorectal Cancer Patients With Uncommon Metastases Treated With Definitive Radiotherapy}},
  author = {TAO-WEI KE and WILLIAM TZU-LIANG CHEN and SHENG-CHI CHANG and CHE-HUNG LIN and YU-MIN LIAO and YUAN-YAO TSAI and SU-PENG YEH and HUA-CHE CHIANG and HWEI-MING WANG and JI-AN LIANG and CHIA-CHIN LI and CHUN-RU CHIEN},
  journal = {In Vivo},
  year = {2026},
  month = oct,
  doi = {10.21873/invivo.14522},
  url = {https://doi.org/10.21873/invivo.14522},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Prognostic Significance of the ESTRO/EORTC Classification of Oligometastatic Disease for Colorectal Cancer Patients With Uncommon Metastases Treated With Definitive Radiotherapy
AU  - TAO-WEI KE
AU  - WILLIAM TZU-LIANG CHEN
AU  - SHENG-CHI CHANG
AU  - CHE-HUNG LIN
AU  - YU-MIN LIAO
AU  - YUAN-YAO TSAI
AU  - SU-PENG YEH
AU  - HUA-CHE CHIANG
AU  - HWEI-MING WANG
AU  - JI-AN LIANG
AU  - CHIA-CHIN LI
AU  - CHUN-RU CHIEN
PY  - 2026
DA  - 2026/10/29
JO  - In Vivo
DO  - 10.21873/invivo.14522
UR  - https://doi.org/10.21873/invivo.14522
AB  - Background/Aim: Prognostic significance of ESTRO/EORTC classification (Lancet Oncol. 21:e18-e28) for colorectal cancer patients with oligometastatic disease at uncommon sites unfit for surgery is unclear.  Patients and Methods: We conducted a retrospective study of colorectal cancer patients with post-surgical oligometastatic disease at uncommon sites treated with definitive radiotherapy. We identified eligible patients via in-house databases. Clinical, disease, treatment, and outcome data were obtained through medical-record review, with classifications determined by consensus among the attending physicians. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method. Cox regression models were used to investigate the potential prognostic factors including the ESTRO/EORTC classification. We also estimated the incidence of local progression.  Results: We identified 59 eligible patients treated from Dec 2012 to Sep 2025. After a median follow-up of 28 months (range=3-145 months), the 5-year OS, PFS, and incidence of local progression were 24%, 10%, 66% respectively. Induced oligoprogression was associated with inferior PFS (adjusted hazard ratio 3.82, p=0.004) but not OS.  Conclusion: ESTRO/EORTC classification was associated with outcomes for colorectal cancer patients with oligometastatic disease at uncommon sites treated with definitive radiotherapy. Future studies are needed to validate our findings.
SN  - 0258-851X
SN  - 1791-7549
ER  -